Welcome to our dedicated page for Fulgent Genetics SEC filings (Ticker: FLGT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Fulgent Genetics, Inc. (NASDAQ: FLGT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Fulgent is a technology-based company with a laboratory services business and a therapeutic development business, and its SEC reports offer detailed information on both areas. Investors can review annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K to understand how the company presents its financial condition, results of operations, and material events.
Fulgent’s earnings-related 8-K filings reference press releases that discuss revenue, core revenue, GAAP and non-GAAP income or loss, gross profit and margin, and adjusted EBITDA. These filings also describe how the company defines and reconciles non-GAAP measures to the most directly comparable GAAP metrics, and how management uses these measures to evaluate performance. For those analyzing FLGT stock, these documents are a primary source for understanding trends in the laboratory services and therapeutic development segments, as well as the company’s cash position and stock repurchase activity.
In addition to financial results, Fulgent uses Form 8-K to report other significant developments, such as preliminary clinical data from its oncology programs. For example, the company has filed an 8-K to furnish a press release describing preliminary data from a phase 2 trial of FID-007 in combination with cetuximab in recurrent or metastatic head and neck squamous cell carcinoma. Such filings provide context on the progress and risk profile of its therapeutic development pipeline.
On this page, users can track FLGT filings in near real time as they are made available through EDGAR. Stock Titan’s tools surface key forms such as 10-K for annual overviews, 10-Q for quarterly updates, and 8-K for material events, with AI-powered summaries that help explain complex sections and highlight important points. For those interested in governance, compensation, or potential insider activity, related SEC documents and forms can also be reviewed alongside the company’s broader disclosure record.
Fulgent Genetics, Inc. director and CEO Ming Hsieh, through The Ming Hsieh Trust, unwound a prepaid variable forward arrangement involving 750,000 shares of common stock. The trust had previously entered this forward contract with an unaffiliated bank in August 2023.
On March 9, 2026, the Hsieh Trust elected to cancel the agreement for all 750,000 shares and paid an aggregate of $10,708,875 to the bank. After this payment and cancellation, those 750,000 shares held by the trust are no longer pledged to the bank.
Following the reported positions, Ming Hsieh holds 900,634 shares directly and has additional indirect holdings, including 7,895,115 and 220,816 shares held by trusts, plus smaller positions of 1,000 shares each in a minor’s account and by an immediate family member.
Ming Hsieh, Chief Executive Officer and Chair of Fulgent Genetics, Inc., reports beneficial ownership of 8,867,303 shares of common stock, representing 30.74% of the 28,844,618 shares outstanding as of March 27, 2026. This includes 7,895,115 shares held by The Ming Hsieh Trust, which alone represents 27.37% of the company’s common stock.
Since the prior amendment, Hsieh’s position changed mainly through the vesting of multiple restricted stock unit awards and performance-based RSUs, with a portion of shares sold or withheld to cover tax obligations. The Trust also terminated two pre-paid forward arrangements covering a total of 1,550,000 shares. A large block of Trust shares remains pledged as security under a pre-paid forward arrangement and as collateral for a credit facility, and Hsieh shares voting and dispositive power over additional shares held by a Dynasty Trust and an immediate family member.
Fulgent Genetics, Inc. is asking stockholders to vote at its 2026 Annual Meeting on May 14, 2026 at 9:00 a.m. Pacific Time in El Monte, California. Investors will elect four directors for one-year terms, ratify Deloitte & Touche LLP as auditor for 2026, cast an advisory vote on named executive officer pay, and vote on the new 2026 Equity Incentive Plan. The proxy details ownership levels, with directors and executive officers as a group holding a significant stake, outlines board committee structure and independence, and explains the company’s pay-for-performance philosophy, risk controls, and cybersecurity and sustainability oversight.
Fulgent Genetics completed two related transactions to expand its pathology footprint. Its Inform Diagnostics subsidiary closed a Purchase and Sale Agreement to acquire all equity of dermatopathology lab StrataDx for approximately $13.5 million in cash, subject to post-closing adjustments. It also closed an Asset Purchase Agreement to buy substantially all assets and certain liabilities of Bako Diagnostics for approximately $43.4 million in cash. A joint press release cites a combined purchase price of about $56.9 million for the Bako and StrataDx acquisitions. In connection with the asset deal, Fulgent assumed a lease for roughly 29,099 square feet of lab and office space in Alpharetta, Georgia, running through July 31, 2032, with base rent of $15.54 per square foot from August 1, 2025 and 2% annual increases, plus operating expenses. Required acquired-business financial statements and pro forma financial information will be provided by amendment.
Fulgent Genetics, Inc. director and CEO Ming Hsieh, a more than ten percent owner, restructured a prior derivative arrangement tied to company stock. A trust associated with him had entered a prepaid variable forward contract in 2023 covering up to 750,000 shares of common stock.
On March 9, 2026, The Ming Hsieh Trust cancelled this agreement for all 750,000 shares and paid the counterparty an aggregate of $10,708,875. After this payment, those 750,000 shares are no longer pledged to the bank and remain held by entities associated with Hsieh.
Following these actions, Hsieh holds 900,634 common shares directly, and additional common shares indirectly, including 7,895,115 by trust, 220,816 by trust, 1,000 in a Uniform Transfers to Minors Act account, and 1,000 held by an immediate family member.
Fulgent Genetics President and COO Jian Xie reported several tax-related share withholdings of company common stock. On February 26, 2026, 1,140 shares were disposed of at $24.7600 per share to cover tax obligations from vesting restricted stock units. On March 1, 2026, additional tax-withholding dispositions of 1,079 and 8,147 shares occurred at $15.3300 per share. After these transactions, his direct holdings were reported as 375,313 shares of common stock. Separately, 220,816 shares are held indirectly by The Hsieh Family Dynasty Trust, for which Mr. Xie serves on the investment committee and disclaims beneficial interest except for any pecuniary interest.
Fulgent Genetics, Inc. CFO and Treasurer Paul Kim reported several tax-withholding dispositions of common stock tied to previously granted restricted stock units. On February 26 and March 1, 2026, shares were withheld at prices of $24.76 and $15.33 to cover associated tax obligations rather than open-market sales.
Fulgent Genetics Chief Scientific Officer Hanlin Gao reported tax-withholding share dispositions related to restricted stock unit vesting. On February 26, 2026 and March 1, 2026, several small blocks of common stock were withheld at prices of $24.76 and $15.33 per share to cover tax obligations, leaving Gao with direct ownership of just under 1.0 million shares after these administrative transactions.
Fulgent Genetics, Inc. director and CEO Ming Hsieh reported tax-related share dispositions rather than open-market sales. On March 1, 2026, 17,566 common shares at $15.33 per share were withheld to cover tax obligations from vested restricted stock units, leaving him with 900,634 directly held shares.
On February 26, 2026, a prior tax-withholding disposition of 2,949 shares at $24.76 per share left him with 918,200 directly held shares at that time. Indirect holdings as of that date include 7,895,115 shares held by the Dynasty Trust, 220,816 by The Ming Hsieh Trust, and 1,000-share positions in a Uniform Transfers to Minors Act account and an immediate family member’s account.